Last reviewed · How we verify

NCT07231783: ATLAS 2

The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults

Recruiting now NA Last updated 31 March 2026
What this trial tests

NA trial testing Placebo in Healthy Aging in 120 participants. Currently enrolling.

Timeline
10 December 2025
Primary endpoint
31 October 2027
31 October 2027

Quick facts

Lead sponsorAmazentis SA
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment120
Start date10 December 2025
Primary completion31 October 2027
Estimated completion31 October 2027
Sites1 location across Ireland

Drugs / interventions tested

Conditions studied

Sponsor

Amazentis SA — full company profile →

Who can join

Adults 40 to 65, any sex, with Healthy Aging or Muscle Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomised, double-blind, placebo-controlled, parallel study to assess the effects of Urolithin A (Mitopure®) supplementation on muscle strength and performance in healthy middle-aged adults. Participants will be randomized to consume Mitopure® (500 mg), Mitopure® (1000 mg), or placebo once daily for 6 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy Aging

Currently open trials in the same condition.

Other Amazentis SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing